Cytidine and Omega-3 Fatty Acids in Bipolar Disorder
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
The goal of the proposed clinical trial is to assess the effect of oral cytidine and omega-3
fatty acids (O3FA) on bipolar disorder symptoms. This study is a 4-month, randomized,
parallel-group, double-blind, placebo-controlled pilot study of a combination of cytidine and
omega-3 fatty acids in 90 recently ill subjects with bipolar disorder. During the 16 week
period of the study, subjects are assigned to one of three groups: 1) omega-3 fatty acids +
cytidine supplementation, 2) omega-3 fatty acids supplementation alone, and 3) placebo
supplementation.